Biomica Signs an Agreement with Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic-Resistant Bacteria

 Biomica Signs an Agreement with Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic-Resistant Bacteria

Biomica Signs an Agreement with Weizmann Institute of Science to Develop a Selective Treatment Against Antibiotic Resistant Bacteria

Shots:

  • Biomica collaborated with Weizmann Institute of Science to develop a selective treatment against antibiotic-resistant strains of Staphylococcus aureus infection, targeting a specific microbe while maintaining the microbiome of the patients’ gut.
  • Biomica has in-licensed IP rights of Prof. Ada E. Yonath’s work and discoveries in the high-resolution crystal structure, allowing a high degree of specificity with Biomica’s computational technology, enabling the development of selective, narrow-spectrum antibiotics
  • The collaboration will put Prof. Yonath’s achievements into practice, to resolve a substantial, unmet clinical need, by developing a highly selective solution to the resistance of Staphylococcus aureus

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Linkedin

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post